Recent

% | $
Quotes you view appear here for quick access.

Heartware International Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tonasket75 tonasket75 Nov 16, 2010 7:30 PM Flag

    These devices have little benefit and patients

    By the way the study if you read it was just over 100 patients. This again is my point, few patients, the power of the study very low.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You really need to get off the BTT population bandwagon that you are stuck on and research how long patients in Europe are living with LVAD's. The recent news re Heartware is a milestone in the space they were evaluated at. Sorry if the spike in price blew out your short position.

      If a patient needs bi-ventricular support then the only option is a temp artificial BTT device such as Syncardia to get them to TX. You may be surprised to find out just how long patients have lived on this device as well as others. Look it up.

      However if the left heart is the issue as it is in about 70% of all class 4 heart failure patients and if they are not a candidate for a TX, then DT therapy is where the excitement is right now. That is what the market is following, not your path that you are stuck on. You can discuss biological solutions, ie stems cells, etc, however despite all the research going on, that is clearly not here right now for these type of patients, which leaves you with mechanical support.

      You may be surprised to find out that patient are living with these devices are 3-5 years out already. According to you, they would have all been dead 3-5 years ago, and this is Europe...socialized medicine, so save the economic argument for another day. CMS will figure this out, not you. Your juvenile posts and analysis show incredible clinical ignorance.

 
HTWR
57.980.00(0.00%)Aug 22 4:00 PMEDT